{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"130","upperLimit":"262","value":"197"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"-Defined as the interval from the start of study therapy to death from any cause","dispersionType":"Full Range","groups":[{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG000","title":"Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG001","title":"Cohort B: Epithelial Origin Solid Tumors w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG002","title":"Cohort C: NSCLC or Non-NSCLC w/Corticosteroids"}],"paramType":"MEDIAN","populationDescription":"One participant in Cohort A was lost to follow-up and is not evaluable for this outcome measure. There were not any participants enrolled to Cohort B or Cohort C.","reportingStatus":"POSTED","timeFrame":"Up to 2 years after completion of treatment (estimated to be 2 years and 6 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"days"}